Major New VC Fund To Support Australian Biotech
This article was originally published in PharmAsia News
A leading Australian venture capital firm has raised the largest ever amount for a private investment fund in the life sciences sector in the country, which will support both early- and mid-stage biotech and device research.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.